Being heard on all-oral therapy for resistant TB

A study, published in The Lancet Infectious Diseases, compared outcomes up to 24 months after treatment initiation for patients with rifampicin-resistant TB in South Africa treated with a short, all-oral bedaquiline-containing regimen, or a short, injectable-containing regimen.